Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy

Ruiz-Mateos, Ezequiela; de la Rosa, Rafaela; Franco, Jaime Ma; Martinez-Moya, Manuelb; Rubio, Amaliac; Soriano, Nataliaa; Sanchez-Quijano, Armandoa; Lissen, Eduardoa; Leal, Manuela

Basic Science

Objective: Immune reconstitution after highly active antiretroviral therapy (HAART) in HIV-infected patients has led to an increase in the number of new CD4 T lymphocytes. Neolymphopoiesis in the thymus has been proposed as a mechanism in T-cell regeneration. Nevertheless, factors involved in the regeneration of T cells by thymic-dependent pathways in HIV-infected patients under HAART are still unknown and might be of relevance in HIV infection. The aim of this work was to study the role of IL-7 in the thymic rebound of HIV-infected adults under HAART.

Design: To study the association between IL-7 and thymic function-related markers, these variables were measured in 49 antiretroviral-naive HIV-infected patients at baseline and at weeks 12, 24, 36 and 48 of treatment.

Methods: Thymic function-related markers: thymic volume, naive phenotype, and T-cell receptor excision circles (TREC) bearing-cells, were evaluated by computed tomography, flow cytometry, and quantitative polymerase chain reaction, respectively. IL-7 levels were evaluated using a high sensitivity colorimetric enzyme-linked immunosorbent assay.

Results: At baseline, we found an inverse correlation between IL-7 levels and thymic function-associated parameters: thymic volume, naive T cells and TREC-bearing cells. After 48 weeks of therapy increased levels of thymic function-related markers along with a significant decrease in IL-7 levels were found. IL-7 levels at baseline were the only independently associated variable with respect to changes in thymic volume at weeks 12, 24 and 48 of follow-up.

Conclusion: These data suggest that IL-7 plays an important role in thymic rebound in adult HIV-infected patients under HAART.

Author Information

From the aViral Hepatitis and AIDS Study Group, and bDepartment of Radiology, Virgen del Rocío University Hospital, and cDepartment of Medical Biochemistry and Molecular Biology, University of Seville, Seville, Spain.

Correspondence to: Manuel Leal MD, PhD, Grupo de Estudio Hepatitis Vírica y SIDA. Department of Internal Medicine, Virgen del Rocío University Hospital. Seville, Spain. Tel: +34 955 012396; fax: +34 955 012390; e-mail: mleal@cica.es

Received: 5 July 2002; revised: 28 October 2002; accepted: 29 November 2002.

Article Outline
Back to Top | Article Outline


The role of the thymus in the regeneration of naive T cells has been suggested in T-cell depletion scenarios [1], including immunological recovery after highly active retroviral therapy (HAART) in HIV-infected patients [2–8]. Increments in naive T-cell absolute numbers have been observed in both children and adult patients after HAART [9], as well as increments in the number of cells carrying a molecular marker of a recent thymic emigrant, T-cell receptor excision circles (TREC) [2–4,6]. Thymic volume measurement using radiological methods [5–8] has also been useful to determine that thymic function might be involved in the repopulation of T cells. Using these tools, we have recently reported an increase in thymic function during 48 weeks under HAART in adult HIV-infected patients [6].

Factors involved in the thymic rebound in HIV-infected patients under HAART are still unknown and might be of relevance in HIV infection. IL-7 could be a good candidate for the following reasons: (i) IL-7 is a pleiotropic and non-redundant cytokine [10] that plays a critical role in the survival, proliferation and development of B and T cell precursors and naive T cells [11–17]. (ii) In animal models, it enhances the peripheral expansion of mature T cells after T-cell depletion in both thymus-deficient [18] and thymus-bearing hosts, although IL-7 was found to enhance preferentially the thymic-dependent pathways in T-cell regeneration [19]. It has recently been observed that the administration of exogenous IL-7 in thymic organ cultures and mice enhances the generation of TREC-bearing cells [20]. (iii) In humans, an inverse correlation between CD4 cell numbers and IL-7 serum levels has been observed in different T-cell depletion scenarios [21], including HIV infection [21–24]. These data provide evidence that IL-7 is a master regulator of T-cell homeostasis [21,25]. The aim of this work was to evaluate the role of IL-7 in thymic rebound in adult HIV-infected patients under HAART.

Back to Top | Article Outline

Patients and methods

In August 1998, the Viral Hepatitis and AIDS Study Group of Virgen del Rocio University Hospital began a study in order to determine the role of the thymus in the repopulation of T cells in adult patients under HAART. From that date, a total of 54 consecutive antiretroviral-naive HIV-infected patients starting HAART were asked to participate in the study. Up to February 2002, 49 patients had agreed to participate. HAART was defined as a combination of at least two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor. Patients were evaluated at baseline and at weeks 12, 24, 36 and 48 of treatment. All patients reported therapy compliance equal to or higher than 95%. Each timepoint was analysed for CD4, CD8, and CD3 T cell subsets and HIV-1-RNA levels in fresh samples. Isolated peripheral blood mononuclear cells (PBMC) were kept frozen in liquid nitrogen, and serum samples were kept at −20°C until further determinations. Forty-seven patients had available samples for TREC determination. Thoracic computed tomography (CT) for measuring thymic volume was taken in all patients at baseline and at weeks 12, 24 and 48 of treatment. Written informed consent was obtained from all patients, and the ethical committee of the Hospital approved the study.

Back to Top | Article Outline
IL-7 determinations

The determination of IL-7 levels was performed using a high sensitivity colorimetric enzyme-linked immunosorbent assay (IL-7 immunoassay kit; R&D System QuantikineHS, Minneapolis, MN, USA) according to the manufacturer's recommendations.

Back to Top | Article Outline
Thoracic computed tomography

Mediastinic CT was performed using a modified previously described method [26]. Briefly, coded samples were always measured by the same radiologist using a 3000 GE Sytec Scanner using 5 mm thick contiguous sections at 5 mm intervals. Thymic tissue was carefully delimited in all the slices between the first and the last in order to exclude mediastinic fat infiltration (a high density for soft tissue and a low density for surrounding fat). CT Sytec version 4 software (General Electrics Medical Systems, Milwaukee, WI, USA) integrated all the defined thymic areas along the slices (the first and last slice volumes being automatically halved to account for partial volume averaging) to calculate thymic volume.

Back to Top | Article Outline
Flow cytometry

At each timepoint, CD4, CD8, CD3, CD19 (B cells), and CD16+CD3 (natural killer cells) absolute numbers were determined in fresh samples, as previously described [9]. Briefly, a frozen aliquot was used to determine the percentages of naive CD4 T cells (CD4+CD45RA+CD45RO), memory CD4 T cells (CD4+CD45RACD45RO+), naive CD8 T cells (CD8+CD45RA+CD11alow), and memory CD8 T cells (CD8+CD45RACD11ahigh). Naive and memory CD4 and CD8 T-cell absolute numbers were calculated according to CD4 and CD8 T-cell counts obtained from fresh blood samples.

Back to Top | Article Outline
T-cell receptor excision circle-bearing cells quantification in peripheral blood mononuclear cells

One proposed molecular marker for the determination of recent thymic cell emigrants is the quantification of TREC generated during the rearrangement of T-cell receptor genes. A polymerase chain reaction (PCR)-based method for quantifying the δRec– ΨJα TREC number has been described by Douek et al. [2]. We have adapted this method to a real-time PCR using a LightCycler (Roche Molecular Biochemicals, Mannheim, Germany) for the quantification of both the characteristic signal-joint sequences harboured in the generated TREC and the β-globin gene (in order to normalize by DNA content) [6]. TREC levels in each PBMC sample were determined using a standard curve of a cloned signal-joint fragment of 375 base pairs (bp) obtained from a pediatric thymic sample [6]. In addition to the TREC per 106 PBMC, the absolute counts of TREC/μl was derived for each sample. Because all the TREC in PBMC are included in the CD3 subpopulation, the TREC/106 PBMC proportion was corrected by the percentage of CD3 cells found by flow cytometry in the PBMC, yielding the number of TREC/106 CD3 cells. This proportion was then multiplied by the absolute CD3 cell counts obtained in fresh blood by flow cytometry.

Back to Top | Article Outline
HIV-1-RNA quantification

Plasma HIV-1 RNA was measured by a quantitative PCR (HIV Monitor test kit version 1.5; Roche Molecular Systems, Hoffman-La Roche, Basel, Switzerland) according to the manufacturer's instructions. This assay has a detection limit of 50 HIV-1-RNA copies/ml.

Back to Top | Article Outline
Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences software package (SPSS 10.0, Chicago, Illinois, USA). All continuous variables were expressed as mean ± standard error of the mean (SEM). Categorical variables were expressed as the number of cases (percentage). Pearson's correlation coefficient analysis was used to assess bivariate correlations between all the variables, with the exception of TREC-bearing cells, in which Spearman's test was used because this variable did not follow a normal distribution. An analysis of variance test for repeated measurements was used to denote significant changes during the follow-up, and to compare these values with baseline values corrected for multiple comparisons. Friedman and Wilcoxon tests were used for TREC-bearing cell measurements because a small number of patients had all the determinations during the follow-up (n = 11). Multiple linear regression was performed to assess independent associations between variables using a stepwise procedure. Predictor variables were considered for inclusion in the statistical model if the association with the parameter of interest (changes in thymic volume versus baseline) were observed in the univariate analysis (P < 0.1) or if the predictor variable had previously been related to thymopoiesis (i.e. age).

Back to Top | Article Outline


Baseline analysis

Patients’ baseline characteristics are summarized in Table 1. The correlation between baseline IL-7 levels and some parameters of interest was analysed. An inverse correlation was found with total, memory and naive CD4 T-cell counts, with naive CD8 T-cell counts, with total naive T-cell counts (naive CD4 plus naive CD8 T cells), with TREC-bearing cells, and with thymic volume. No correlation was found between IL-7 levels and the rest of the parameters studied (Table 2). The correlation between IL-7 levels and thymic function-associated parameters is shown in Fig. 1.

Back to Top | Article Outline
Follow-up analysis

For a better understanding of the association between IL-7 levels and the thymic function of patients under HAART, changes in IL-7 levels, thymic volume, T-cell phenotype and TREC-bearing cells were analysed during follow-up. In all patients, HIV-1-plasma viremia decreased more than 1 log10 copies/ml during follow-up, reaching viral load levels below the limit of detection (≤ 50 copies/ml) in more than 90% of them. During follow-up, increased levels of thymic function-related markers along with a significant decrease in IL-7 levels were found. Memory T cells did not increase after 48 weeks under HAART. IL-7 levels were lower during follow-up compared with baseline levels at statistical significance (P < 0.05) (Fig. 2a). All thymic function-associated parameters showed a significant increase during follow-up compared with baseline values (P < 0.05), with the exception of TREC-bearing cells at week 48 of follow-up (P = 0.671) (Fig. 2b–d). On the other hand, statistical significance was not reached during follow-up when total memory T cells (memory CD4 T cells plus memory CD8 T cells) were analysed compared with baseline values (P > 0.05) (Fig. 2c). Total CD8 T-cell counts did not significantly increase during the follow-up (P > 0.05).

Back to Top | Article Outline
IL-7 is independently associated with changes in thymic volume

Multiple linear regression was performed to consider changes in thymic volume at each timepoint of follow-up versus baseline, as a dependent variable. Variables showing a univariate association level of less than 0.1 with changes in thymic volume were entered into the multivariate analysis as potential independently associated variables (Table 3). Only baseline IL-7 levels were independently associated with changes in thymic volume at weeks 12 (P = 0.019), 24 (P = 0.008) and 48 (P = 0.001) versus baseline. Fig. 3a–c shows the correlation between IL-7 levels at baseline and the changes in thymic volume. No variables were found to be independently associated with changes in total naive T cells or changes in TREC-bearing cell numbers at any timepoint of follow-up compare with baseline (data not shown).

Back to Top | Article Outline


The data presented here suggest that higher IL-7 levels produced in response to T-cell depletion before therapy may activate thymic rebound in adult HIV-infected patients under HAART.

Thymic tissue measurement is now an accepted biological marker for thymus function [5]. We have recently reported an increase in thymic function, measuring thymic volume, as early as 12 weeks after HAART in HIV-infected patients. Also, a direct correlation between thymic volume and TREC- bearing cells and an inverse correlation between thymic volume and age has been found, supporting the reliability of the technique for measuring the thymus [6]. We have also reported that thymic volume was an independent predictor for CD4 T-cell repopulation in HIV-infected adults under HAART [27].

The role of IL-7 in T-cell homeostasis in response to T-cell depletion has not been found for other cytokines and soluble factors [19,21,22]. In animal models, it has been shown that IL-7 enhances the peripheral expansion of mature T cells [18], and preferentially thymic-dependent pathways in T-cell generation after T-cell depletion [19]. Recent studies have shown that the administration of exogenous IL-7 to in-vitro systems and mice increased the number of TREC-bearing cells produced by the thymus [20]. These observations and others [28,29] strongly suggest an important role of this cytokine in the regeneration of T cells by the thymus, at least in murine models.

The inverse correlation between IL-7 levels and total CD4 T cells before therapy supports the important role of IL-7 in response to T-cell depletion. This is the first study in which an inverse correlation between IL-7 levels and thymic volume before therapy was observed. Consequently, IL-7 seems not to be necessarily produced in the thymus, but probably in the periphery. Patients with an absence of a radiological image of the thymus thus had higher levels of IL-7. These data support findings previously reported, in which IL-7 in untreated patients should preferentially be produced by peripheral lymphoid organs in response to T-cell depletion [22].

A significant decrease in IL-7 levels during follow-up compared with baseline levels was observed, probably in response to the significant increase in total CD4 T-cells during follow-up. These results suggest that the homeostatic response is fast and sensitive in HIV replication control after HAART. The increase in thymic function-associated parameters and the stability in the memory T-cell subset during follow-up suggest that repopulation of HIV-infected adults under HAART is preferentially led by the thymus, at least in the first 12 weeks of follow-up. We speculate that the difference between naive and memory T cells during follow up could be explained partly by the different mechanisms of homeostatic cell proliferation. Naive T cells proliferate relatively slowly and depend on the contact of self-major histocompatibility complex and peptide ligands. In T-cell depletion conditions, when the total number of naive T cells decreases below a certain level, IL-7 is increased because of a reduction in the number of T-cell receptors and MHC–peptide interactions [17]. The fast MHC-independent homeostatic regulation of memory T cells could perhaps explain why IL-7 seems not to be involved in their expansion.

The IL-7 level was the only variable associated with changes in thymic volume by multiple linear regression analysis during the follow-up. These data strongly suggest that a baseline IL-7 level is a factor that might trigger thymic rebound in HIV-infected adults under HAART. Two conditions have to be considered, that there is no irreversible damage of the thymus and no irreversible damage of the peripheral lymphoid organs. No parameter was independently associated with changes in either naive T cells or TREC-bearing cells at each timepoint compared with the baseline. This fact could be explained because the naive T-cell number is not a true thymic-related marker in HIV infection. Therefore, a naive T-cell increase could be caused by peripheral expansion after HAART [30,31]. The small number of patients could explain the absence of a correlation between IL-7 levels and changes in TREC-bearing cell counts during follow-up. Also, it might be possible that thymic volume measurement could be more reliable and a better tool for the determination of thymic function compared with TREC-bearing cell determination [27].

In our opinion, IL-7 should not be considered to be an immunomodulatory therapy, at least in HIV infection, because patients with irreversible damage to the thymus can not produce new T cells independently of the levels of IL-7. Moreover, the administration of IL-7 in order to increase T-cell counts is also discouraged, because this cytokine has been shown to enhance HIV replication [22,32–34]. HIV infection could thus be considered a ‘soil immunodeficiency’ and not a ‘signal immunodeficiency'. Nevertheless, the potential use of IL-7 as a therapy in other types of immunocompromised patients might be indicated.

In summary, our data show for the first time in humans that IL-7 might be involved in the activation of increased thymic volume after T-cell depletion, and specifically in adult HIV-infected patients undergoing HAART. The absence of a radiological image of the thymus in some patients with higher levels of IL-7 also supports the theory that IL-7 is mainly produced in peripheral organs in untreated patients. New soluble factors involved in the modification of thymic function in patients under HAART and new therapeutic strategies in order to improve immune reconstitution in these patients are under research.

Back to Top | Article Outline


The authors would like to thank the individuals who participated in this study, as well as M. Olivera and A. Gayoso for excellent technical assistance.

Sponsorship: This work was supported by research grants from the Fondo para la Investigación y Prevención del SIDA en España (FIPSE 2132/00 and FIPSE 12304/02) integrated by the Ministerio de Sanidad y Consumo, Abbott Laboratories, Boehringer Ingelgeim, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme and Roche, Fondo de Investigaciones Sanitarias (FIS 00/0521), and by the kind support of Fundación Wellcome, España. This work was also partially supported by Red de Investigación en SIDA (RIS) by Ministerio de Sanidad y Consumo (SPAIN).

Back to Top | Article Outline


1.Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143–149.
2.Douek DR, McFarland P, Keiser E, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during treatment of HIV infection. Nature 1998, 396:690–695.
3.Zhang L, Lewin SR, Markowitz M, Lin HH, Skulsky E, Karanicolas R, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999, 190:725–732.
4.Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, et al. Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001, 15:1749–1756.
5.McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998, 11:2301–2308.
6.Franco JM, Rubio A, Martinez-Moya M, Leal M, Merchante E, Sánchez-Quijano A, et al. T cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002, 99:3702–3706.
7.Vigano A, Vella S, Saresella M, Vanzulli A, Bricalli D, Di Fabio S, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000, 14:251–261.
8.Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000, 181:141–147.
9.Franco JM, León-Leal JA, Leal M, Cano-Rodriguez A, Pineda JA, Macias J, et al. CD4+ and CD8+ T-lymphocytes regeneration after antiretroviral therapy in HIV-1 infected children and adult patients. Clin Exp Immunol 2000, 119:493–498.
10.von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interlekin-7 (IL-7) gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995, 181:1519–1526.
11.Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL, et al. B cell precursor growth-promoting activity: purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988, 167:988–1002.
12.Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, et al. Stimulation of B-cell progenitors by cloned murine inteleukin-7. Nature 1988, 333:571–573.
13.Henney CS. Interleukin 7: effects on early events in lymphopoiesis. Immunol Today 1989, 10:170–173.
14.Murray R, Suda T, Wrighton N, Lee F, Zlotnik A. IL-7 is a growth and maintenance factor for mature and immature thymocyte subsets. Int Immunol 1989, 1:526–531.
15.Maki K, Sunaga S, Komagata Y, Kodaira Y, Mabuchi A, Karasuyama H, et al. Interleukin 7 receptor-deficient mice lack gammadelta T cells. Proc Natl Acad Sci U S A 1996, 93:7172–7177.
16.Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev 1998, 165:13–28.
17.Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, et al. IL-7 is critical for homeostatic proliferation and survival of naïve T-cells. Proc Natl Acad Sci U S A 2001, 98:8732–8737.
18.Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. IL-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001, 97:1525–1533.
19.Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE. IL–7 increases both thymic-dependent and thymic independent T-cell regeneration after bone marrow transplantation. Blood 2001, 97:1491–1497.
20.Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human thymus function. Blood 2002, 99:2851–2858.
21.Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, et al. A potential role for IL-7 in T-cell homeostasis. Blood 2001, 97:2983–2990.
22.Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1 mediated T-cell depletion: implication for T-cell homeostasis. Nat Med 2001, 7:73–79.
23.Llano A, Barretina J, Gutierrez A, Blanco J, Cabrera C, Clotet B, et al. IL-7 in plasma correlates with CD4+ T-cell depletion and may be associated with emergence of SI variants in HIV-1+ individuals. J Virol 2001, 75:10319–10325.
24.Darcissac ECA, Vidal V, de la Tribonniere X, Mouton Y, Bahr GM. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analices in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin Exp Immunol 2001, 126:287–294.
25.Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001, 22:564–571.
26.Choyke PL, Zeman RK, Gootenberg JE, Greenberg JN, Hoffer F, Frank JA. Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. Am J Roentgenol 1987, 149:269–272.
27.De la Rosa R, Leal M, Rubio A, Martínez-Moya M, Delgado J, Ruíz-Mateos E, et al. Baseline thymic volume is a predictor for CD4+ T-cell repopulation in adult HIV-infected patients under highly active antiretroviral therapy. Antivir Ther 2002, 7:159–163.
28.Morrisey PJ, Conlon P, Braddy S, Williams DE, Namen AE, Mochizuki DY. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol 1991, 146:1547–1552.
29.Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 1996, 88:1887–1894.
30.Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar RL, Natarajan V, et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A 2000, 97:13778–13783.
31.Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95:249–255.
32.Guillemard E, Nugeyre MT, Chene L, Schmitt N, Jacquemot C, Barre-Sinoussi F, et al. IL-7 and infection itself by HIV-1 favor virus persistence in mature CD4+CD8−CD3+ thymocytes through sustained induction of Bcl-2. Blood 2001, 98: 2166–2173.
33.Dardalhon V, Jaleco S, Kinet S, Herpers B, Steinberg M, Ferrand C, et al. IL-7 differentially regulates cell cycle progression and HIV-1 based vector infection in neonatal and adult CD4+ T cells. Proc Natl Acad Sci U S A 2001, 98:9277–9282.
34.Steffens CM, Managlia EZ, Landay A, Al-Harthi L. Interleukin-7-treated naive T-cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood. 2002, 99:3310–3318.

Cited By:

This article has been cited 2 time(s).

HIV infection: pre-highly active antiretroviral therapy IL-7 plasma levels correlate with long-term CD4 cell count increase after treatment
Beq, S; Rannou, M; Fontanet, A; Delfraissy, J; Thèze, J; Colle, J
AIDS, 18(3): 563-565.

PDF (164)
Limited efficiency of endogenous interleukin-7 levels in T cell reconstitution during HIV-1 infection: will exogenous interleukin-7 therapy work?
Rethi, B; Vivar, N; Sammicheli, S; Chiodi, F
AIDS, 23(7): 745-755.
PDF (232) | CrossRef
Back to Top | Article Outline

Highly active antiretroviral therapy; HIV; IL-7; immune reconstitution; thymus

© 2003 Lippincott Williams & Wilkins, Inc.